Pacific Edge Limited

ASX:PEB Stock Report

Market Cap: AU$96.1m

Pacific Edge Valuation

Is PEB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PEB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PEB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PEB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PEB?

Key metric: As PEB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PEB. This is calculated by dividing PEB's market cap by their current revenue.
What is PEB's PS Ratio?
PS Ratio4.7x
SalesNZ$22.62m
Market CapNZ$106.36m

Price to Sales Ratio vs Peers

How does PEB's PS Ratio compare to its peers?

The above table shows the PS ratio for PEB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average19.6x
BTG Beroni Group
39.8xn/aAU$75.9m
ACW Actinogen Medical
8x20.0%AU$79.9m
ARX Aroa Biosurgery
4x21.3%AU$275.9m
RAD Radiopharm Theranostics
26.6x50.2%AU$52.2m
PEB Pacific Edge
4.7xn/aAU$106.4m

Price-To-Sales vs Peers: PEB is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (12.9x).

Price to Sales Ratio vs Industry

How does PEB's PS Ratio compare vs other companies in the AU Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
IMC Immuron
3.7x59.7%US$11.25m
BNO Bionomics
2.4x-5.3%US$9.52m
CHM Chimeric Therapeutics
0.8xn/aUS$3.70m
EX1 Exopharm
1.4xn/aUS$3.29m
PEB 4.7xIndustry Avg. 11.0xNo. of Companies10PS01632486480+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PEB is good value based on its Price-To-Sales Ratio (4.7x) compared to the Australian Biotechs industry average (11x).

Price to Sales Ratio vs Fair Ratio

What is PEB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PEB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PEB's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PEB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.14
AU$0.14
+0.5%
3.2%AU$0.15AU$0.14n/a2
Jan ’26AU$0.14
AU$0.14
+4.2%
3.2%AU$0.15AU$0.14n/a2
Dec ’25AU$0.13
AU$0.14
+12.5%
3.2%AU$0.15AU$0.14n/a2
Nov ’25AU$0.13
AU$0.14
+7.7%
9.7%AU$0.15AU$0.13n/a2
Oct ’25AU$0.12
AU$0.12
+0.1%
7.7%AU$0.13AU$0.11n/a2
Sep ’25AU$0.082
AU$0.12
+46.5%
7.7%AU$0.13AU$0.11n/a2
Aug ’25n/a
AU$0.12
0%
7.7%AU$0.13AU$0.11n/a2
Jul ’25AU$0.083
AU$0.12
+44.8%
7.7%AU$0.13AU$0.11n/a2
Jun ’25AU$0.09
AU$0.12
+33.5%
7.7%AU$0.13AU$0.11n/a2
May ’25AU$0.08
AU$0.12
+54.8%
18.5%AU$0.15AU$0.10n/a2
Apr ’25AU$0.075
AU$0.14
+81.5%
10.3%AU$0.15AU$0.12n/a2
Mar ’25AU$0.08
AU$0.14
+70.2%
10.3%AU$0.15AU$0.12n/a2
Feb ’25AU$0.10
AU$0.13
+29.6%
14.3%AU$0.15AU$0.11n/a2
Jan ’25AU$0.098
AU$0.13
+35.2%
12.3%AU$0.15AU$0.12AU$0.142
Dec ’24AU$0.092
AU$0.13
+43.3%
12.3%AU$0.15AU$0.12AU$0.132
Nov ’24AU$0.094
AU$0.14
+47.4%
8.5%AU$0.15AU$0.13AU$0.132
Aug ’24AU$0.13
AU$0.24
+86.3%
56.6%AU$0.44AU$0.15n/a3
Jul ’24AU$0.077
AU$0.24
+214.6%
56.6%AU$0.44AU$0.15AU$0.0833
Jun ’24n/a
AU$0.53
0%
22.0%AU$0.70AU$0.45AU$0.093
May ’24n/a
AU$0.55
0%
20.3%AU$0.70AU$0.45AU$0.083
Apr ’24AU$0.38
AU$0.55
+45.6%
19.3%AU$0.70AU$0.45AU$0.0753
Mar ’24AU$0.42
AU$0.55
+30.8%
19.3%AU$0.69AU$0.44AU$0.083
Feb ’24AU$0.46
AU$0.55
+19.4%
19.3%AU$0.69AU$0.44AU$0.103
Jan ’24n/a
AU$0.56
0%
19.1%AU$0.71AU$0.45AU$0.0983

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 22:49
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pacific Edge Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anubhav SaxenaBell Potter
null nullBrookline Capital Markets
Gregory MainCredit Suisse